In yesterday’s Wall Street session, Co-Diagnostics Inc. (NASDAQ:CODX) shares traded at $2.52, down -0.40% from the previous session.
CODX stock price is now -18.45% away from the 50-day moving average and -42.90% away from the 200-day moving average. The market capitalization of the company currently stands at $78.20M.
With the price target maintained at $5, Sidoti recently Downgraded its rating from Buy to Neutral for Co-Diagnostics Inc. (NASDAQ: CODX). On December 29, 2021, Sidoti recently initiated its ‘Buy’ rating on the stock quoting a target price of $14, while ‘Maxim Group’ rates the stock as ‘Hold’.
Insiders disposed of 70,020 shares of company stock worth roughly $0.18 million over the past 1 year. A total of 0.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CODX stock. A new stake in Co-Diagnostics Inc. shares was purchased by WALLEYE CAPITAL LLC during the first quarter worth $346,000. TOWNSQUARE CAPITAL LLC invested $169,000 in shares of CODX during the first quarter. In the first quarter, CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. acquired a new stake in Co-Diagnostics Inc. valued at approximately $164,000. ENGINEERS GATE MANAGER LP acquired a new stake in CODX for approximately $127,000. TOWER RESEARCH CAPITAL LLC (TRC) purchased a new stake in CODX valued at around $73,000 in the second quarter. In total, there are 86 active investors with 21.00% ownership of the company’s stock.
On Friday morning Co-Diagnostics Inc. (NASDAQ: CODX) stock kicked off with the opening price of $2.4800. During the past 12 months, Co-Diagnostics Inc. has had a low of $2.26 and a high of $10.11. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 17.00, and a quick ratio of 16.00. The fifty day moving average price for CODX is $3.0784 and a two-hundred day moving average price translates $4.3952 for the stock.
The latest earnings results from Co-Diagnostics Inc. (NASDAQ: CODX) was released for Sep, 2022. According to the Diagnostics & Research Company, earnings per share came in at -$0.08, missing analysts’ expectations of $0.1 by -0.18. This compares to $0.38 EPS in the same period last year. The net profit margin was 28.50% and return on equity was 10.80% for CODX. The company reported revenue of $5.09 million for the quarter, compared to $30.1 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -83.07 percent. For the current quarter, analysts expect CODX to generate $7.98M in revenue.
Co-Diagnostics Inc.(CODX) Company Profile
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.